Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
1999 US. Public Health Service and Infectious Diseases Society of America Guidelines for the prevention of opportunistic infections in persons Infected with human immunodeficiency virus..
MMWR, 48 (1999), pp. 1-59
[2.]
World Health Organization.
Hepatitis C global prevalence.
Weekly Epidemiological Record, 72 (1997), pp. 341-348
[3.]
Global surveillance and control of hepatitis C..
Report of a WHO consultation organized with the Viral Hepatitis Prevention Board, Antwerp, Belgium.
J Viral Hepat, 6 (1999), pp. 35-47
[4.]
World Health Organization.
Hepatitis C global prevalence (update).
Weekly Epidemiological Record, 3 (2000), pp. 18-19
[5.]
Centers for Disease Control and Prevention.
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.
MMWR, 47 (1998), pp. 1-30
[6.]
L.B. Seeff, R.N. Miller, C.S. Rabkin, Z. Buskell-Bales, K.D. Straley-Eason, B.L. Smoak, et al.
45-year follow-up of hepatitis C virus infection in healthy young adults.
Ann Intern Med, 18 (2000), pp. 105-111
[7.]
T. Poynard, P. Bedossa, P. Opolon.
Natural history of liver fibrosis progression in patients with chronic hepatitis C.
Lancet, 349 (1997), pp. 825-832
[8.]
J.P. Zarski, B. Bohn, A. Bastie, J.M. Pawlotsky, M. Baud, F. Bost-Bezeaux, et al.
Characteristics of patients with dual infection by hepatitis B and C viruses.
J Hepatol, 28 (1998), pp. 27-33
[9.]
H. Tsukuma, T. Hiyama, S. Tanaka, M. Nakao, T. Yabuuchi, T. Kitamura, et al.
Risk factors for hepatocellular carcinoma among patients with chronic liver disease.
N Engl J Med, 328 (1993), pp. 1797-1801
[10.]
C. Brechot, F. Jaffredo, D. Lagorce, G. Gerken, K. Meyer zum Buschenferlde, A. Papakonstontinou, et al.
Impact of HBV. HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.
J Hepatol, 29 (1998), pp. 173-183
[11.]
A. Wasley, M. Alter.
Epidemiology of hepatitis C: geographics differences and temporal trends.
Sem Liver Dis, 20 (2000), pp. 1-16
[12.]
G.L. Armstrong, M.J. Alter, G.M. McQuillan, H.S. Margolis.
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States.
Hepatology, 31 (2000), pp. 777-782
[13.]
Davis GL, Albright JE, Cook S, Rosenberg D. Projecting the future healthcare burden from hepatitis C in the United States. 49th Annual Meeting of the American Association for the Study of Liver Diseases. Chicago, November 1998; III. Abstract 909.
[14.]
J.r. Staples CT, D. Rimland, D. Dudas.
Hepatitis C in the HIV human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effects of coinfection on survival.
Clin Infect Dis, 29 (1999), pp. 150-154
[15.]
A.R. Zanetti, E. Tanzi, S. Paccagnini, N. Principi, G. Pizzocolo, M.L. Caccamo, et al.
Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission.
Lancet, 345 (1995), pp. 289-291
[16.]
D.L. Thomas, S.A. Villano, K.A. Riester, R. Hershow, L.M. Mofenson, S.H. Landesman, et al.
Perinatal transmission of hepatitis C virus from human immunodeficiency virus type-1 infected mothers. Women and Infants Transmission Study.
J Infect Dis, 177 (1998), pp. 1480-1488
[17.]
R.C. Hershow, K.A. Riester, J. Lew, T.C. Quinn, L.M. Mofenson, K. Davenny, et al.
Increased vertical transmission of human immunodeficiency virus from hepatitis C coinfected mothers. Women and Infants Transmision Study.
J Infect Dis, 176 (1997), pp. 414-420
[18.]
E. Lissen, H.J. Alter, M.A. Abad, Y. Torres, M. Pérez-Romero, M. Leal, et al.
Sexual transmisión of hepatitis C virus infection: possible role of coexistent human immunodeficiency virus infection.
Eur J Clin Microbiol Infect Dis, 12 (1993), pp. 827-831
[19.]
B. Soto, L. Rodrigo, M. García-Bengoechea, A. Sánchez-Quijano, S. Riestra, J.I. Arenas, et al.
Heterosexual transmission of hepatitis C virus and possible role of coexistent human immunodeficiency virus infection in the index case. A multicenter study on 427 parings.
J Intern Med, 2236 (1994), pp. 515-519
[20.]
P. Martín, A. Di Bisceglie, C. Kassianides, M. Lisker-melman, J. Hoofnagle.
Rapidly progressive non-A, non-B hepatitis in patients with HIV infection.
Gastroenterology, 97 (1989), pp. 1559-1561
[21.]
M. Eyster, L. Diamondstone, J. Lien, W. Ehmann, S. Quan, J. Goedert.
The natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with HIV. The Multicenter Hemophilia Cohort Study.
J Acquir Immun Def Syndr, 6 (1993), pp. 602-610
[22.]
B. Soto, A. Sánchez-Quijano, L. Rodrigo, J. Del Olmo, M. García-Bengoechea, J. Hernández-Quero, et al.
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.
J Hepatol, 26 (1997), pp. 1-5
[23.]
O. Lesens, M. Deschenes, M. Steben, G. Belanger, C. Tsoukas.
Hepatitis C virus eis related to progressive liver disease in HIV hemophiliacs and should be treated as an opportunistic infection.
J Infect Dis, 179 (1999), pp. 1254-1258
[24.]
F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators.
N Engl J Med, 338 (1998), pp. 853-860
[25.]
K. Bjor, S.S. Froland, Z. Yun, H.H. Sandal, T. Haaland.
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
N Engl J med, 331 (1994), pp. 1607-1611
[26.]
E.J. Gane, B.C. Portmann, N.V. Naumov, H.M. Smith, J.A. Underhill, P.T. Donaldson, et al.
Long-term outcome of hepatitis C infection after liver transplantation.
N Engl J Med, 334 (1996), pp. 815-820
[27.]
B. Cribier, D. Rey, C. Schmitt, J. Lang, A. Kirn, F. Stoll-Keller.
High hepatitis C viremia and impaired antibody response in patients coinfected with HIV.
AIDS, 9 (1995), pp. 1131-1136
[28.]
D.L. Thomas, J.W. Shiih, H.J. Alter, D. Vlahov, S. Cohn, D.R. Hoover, et al.
Effect of human immunodeficiency virus on hepatitis C infection among injecting drug users.
J Infect Dis, 174 (1996), pp. 690-695
[29.]
Y. Benhamou, M. Bochet, V. Di Martino.
Liver fibrosis progression in HIV and hepatitis C virus coinfected patients.
Hepatology, 30 (1999), pp. 1054-1058
[30.]
M. Puoti, M. Bonacini, A. Spinetti, V. Putzolu, S. Govindarajan, S. Zaltron, et al.
Liver fibrosis progression is related to CD4 depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus.
J Infect Dis, 183 (2001), pp. 134-137
[31.]
V. Soriano, J. García-Samaniego, E. Valencia, R. Rodríguez-Rosado, J. Muñóz F, González-Lahoz.
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admisión and death in HIV-infected drug useres.
Eur J Epidemiol, 15 (1999), pp. 1-4
[32.]
M. Puoti, A. Spinetti, A. Ghezzi, F. Donato, S. Zaltron, V. Puztelu, et al.
Mortality for liver disease in patients with HIV infectio: a cohort study.
J Adquir Immune Def Syndr, 24 (2000), pp. 211-217
[33.]
V. Soriano, L. Martín-Carbonero, J. García-Samaniego, M. Puoti.
Mortality due to chronic viral liver disease among patients with human immunodefocency virus.
Clin Infect Dis, 33 (2001), pp. 1793-1795
[34.]
I. Bica, B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, et al.
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.
Clin Infect Dis, 32 (2001), pp. 492-497
[35.]
J. García-Samaniego, M. Rodríguez, J. Berenguer, R. Rodríguez-Rosado, J. Carbó, V. Asensi, et al.
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.
Am J Gastroenterol, 96 (2001), pp. 179-183
[36.]
D.R. Harris, R. Gonin, H.J. Alter, E.C. Wright, Z.J. Buskell, F.B. Hollinger, et al.
The relationship of acute transfusion-associated hepatitis to the development of the cirrhosis in the presence of alcohol abuse.
Ann Itern Med, 134 (2001), pp. 120-124
[37.]
M.S. Sulkowsky, D.L. Thomas, R.E. Chaisson, R.D. Moore.
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
JAMA, 283 (2000), pp. 74-80
[38.]
P. Cacoub, L. Geffray, E. Rosenthal, C. Perronne, P. Veyssier, G. Raguin.
Mortality among human immunodeficiency virus-infected patient with cirrhosis or hepatocelular carcinoma due to hepatitis C virus in French Department of Internal Medicine/Infectious Diseases, in 1995 and 1997.
Clin Infect Dis, 32 (2001), pp. 1207-1214
[39.]
S. Cooper, A.l. Erickson, E.J. Adam, J. Kansopon, A.J. Weiner, D.Y. Chien, et al.
Analysis of a successful immune response against hepatitis C virus.
Immunity, 10 (1999), pp. 439-449
[40.]
F. Lechner, D.K. Wong, P.R. Dunbar, R. Chapman, R.T. Chung, P. Dohrenwend, et al.
Analysis of successful immune response in persons infected with hepatitis C virus.
J Exp Med, 191 (2000), pp. 1499-1512
[41.]
A. Takaki, M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, et al.
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.
Nat Med, 6 (2000), pp. 578-662
[42.]
G. Barbaro, G. Di Lorenzo, A. Asti, M. Ribersani, G. Belloni, B. Grisorio, et al.
Hepatocellular mitochondrial alterations In patients with chorinic hepatitis C. Ultrastructural and biochemical findings.
Am J Gastroenterol, 94 (1999), pp. 2198-2205
[43.]
Y. Benhamou, V. Di Martino, M. Bochet, G. Colombet, V. Thibault, A. Liou, et al.
Factors affecting liver fibrosis in human immunodeficiency virus ans hepatitis C virus coinfected patients: impact of protease inhibitor therapy.
Hepatology, 34 (2001), pp. 283-287
[44.]
Y. Allory, F. Charlotte, Y. Benhamou, P. Opolon, Y. Le Charpentier, T. Poynard.
Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a casecontrol study. The MULTIVIRC group.
Hum Pathol, 31 (2000), pp. 69-74
[45.]
A.C. Sabin, P. Telfer, A.N. Philips, S. Bhagani, C.A. Lee.
The association between hepatitis C virus genotype and human immunodeficiency virus progression in a cohort of hemophilic men.
J Infect Dis, 175 (1997), pp. 164-168
[46.]
G. Greub, B. Lemberger, M. Battegay, P. Group, L. Perrin, H. Furrer, et al.
A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Lancet, 356 (2000), pp. 1800-1805
[47.]
L. Piroth, M. Grappin, L. Cuzin, Y. Mouton, O. Bouchard, F. Raffi, et al.
Hepatitis C virus co-infection es a negative prognostic factor for clinical evolution in human immunodeficiency viruspositive patients.
J Viral Hepat, 7 (2000), pp. 302-308
[48.]
Soriano V, Kirk O, Antunes F. The influence of hepatitis C on the prognosis of HIV: The EuroSIDA Study. XIII Int AIDS Conf, Durban 2000, Abstract ThOrB655.
[49.]
Martin JC, López M, Arranz R, Soriano V. Impact of hepatitis C in HIV-infected individuals in an urban center in Madrid, Spain. 8th Conference on Retroviruses & Opportunistics Infections. Chicago, 2001, Abstract 458.
[50.]
E.S. Daar, H. Lynn, S. Donfield, E. Gomperts, S.J. O'Brien, M.W. Hilgartner, et al.
Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs.
J Infect Dis, 183 (2001), pp. 589-595
[51.]
S. Vento, T. Garófano, C. Renzini, F. Casali, T. Ferraro, J. Conciae.
Fulminant hepatitis associated with hepatitis A virus superinfection in patients ith chronic hepatitis C.
N Engl J Med, 27 (1998), pp. 881-886
[52.]
G. García-Tsao, J.L. Boyer.
Outpatient liver biopsy: how safe is it?.
Ann Intern Med, 118 (1993), pp. 150-153
[53.]
C.H. Janes, K.D. Lindor.
Outcome of patients hospitalized for complications after outpatient liver biopsy.
Ann Intern Med, 118 (1993), pp. 96-98
[54.]
H. Zylberbeg, S. Pol, V. Thiers, M.L. Chaix, D. Lagorce, C. Brechot, et al.
Significance of repeatedly normal aminotransferase activities in HCV infected patients.
J Clin Gastroenterol, 29 (1999), pp. 71-75
[55.]
C.F. Gholson, K. Morgan, G. Catinis, D. Favrot, B. Taylor, E. González, et al.
Chronic hepatitis C with normal aminotransferase levels: a clinical histological study.
Am J Gastroenterol, 92 (1997), pp. 1788-1792
[56.]
N.C. Tassopoulos.
Treatment of patients with chronic hepatitis C and normal ALT levels.
J Hepatol, 31 (1999), pp. 193-196
[57.]
National Institute of Health Consensus Development Conference Panel Statement:.
Management of Hepatitis C.
Hepatology, 26 (1997), pp. 2-10
[58.]
EASL International Consensus Conference on Hepatitis C..
Consensus Statement.
J Hepatol, 39 (1999), pp. 956-961
[59.]
B. Hoen, B. Dumon, M. Harzic, A. Venet, B. Dubeaux, C. Lascoux, et al.
Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-infection: results of the ARNS 053 trial.
J Infect Dis, 180 (1999), pp. 1342-1346
[60.]
J.K. Rockstrob, A. Theisen, R. Kaiser, T. Sauerbruch, U. Spengler.
Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV –coinfected haemophiliacs.
AIDS, 12 (1998), pp. 829-830
[61.]
Panel on Clinical Practices for the Treatment of HIV infection (Department of Health and Human Services and the Henry J. Kaiser Family Foundation). Guidelines for use oif antiretroviral agents in HIV-infected adults and adolescents. Disponible en: http://www.hivatis.org.trtgdlns.html#AdultsAdolescent March 8, 2001.
[62.]
Treatment Recommendatios for Patients with Chronic Hepatitis C: 2001 Version 1.0. Disponible en: http://www.va.gov/hepatitisc/pved/treatmntgdlnes_00.htm October 17, 2001
[63.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon alpha-2b plus ribavirina for 48 weeks or 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic hepatitis infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[64.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Schiffman, W.M. Lee, V.K. Rutsgi, et al.
Interferon alfa-2b monotherapy vs. Interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a US multicenter study.
N Engl J Med, 339 (1998), pp. 1485-1492
[65.]
G.L. Davis, R. Esteban-Mur, V. Rystgi, J. Hoefs, S.C. Gordon, S.C. Trepo, et al.
Interferon alfa-2b alone or in combination with ribavirina for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
N Engl J med, 339 (1998), pp. 1493-1499
[66.]
G.T. Everson, D.M. Jensen, J.R. Craig, D.J. van Leeuwen, V.G. Bain, M.N. Ehrinpreis, et al.
Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or non-fibrotics.
Hepatology, 30 (1999), pp. 271-276
[67.]
S. Zeusen, S.V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, E. Gane, et al.
Peginterferon alpha-2a in patients with chronic hepatitis.
N Engl J Med, 343 (2000), pp. 1666-1672
[68.]
K.L. Lindsay, C. Trepo, T. Heintges, M.L. Schiffman, S.C. Gordon, J.C. Hoefs, et al.
A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon-alfa 2b as initial treatment for chronic hepatitis C.
Hepatology, 34 (2001), pp. 395-403
[69.]
E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, L. Rolart, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[70.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Schiffman, R. Reindollar, et al.
Peginterferon alfa-2b plus ribavirina compared with interferon alfa-2b plus ribavirina for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[71.]
K.R. Reddy, T.L. Wright, P.J. Pockros, M. Schiffman, G. Everson, R. Reindollar, et al.
Efficacy and safety of pegylated (40-kd) interferon alpha 2a compared with interferon alpha-2a in noncirrotic patients with chronic hepatitis C.
Hepatology, 33 (2001), pp. 433-438
[72.]
V. Soriano, R. Bravo, J. García-Samaniego, J. González, P. Odriozola, E. Arroyo, et al.
CD4+ T lymphocitopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C.
AIDS, 8 (1994), pp. 1621-1622
[73.]
A. Landau, D. Batisse, J. Duong, C. Piketty, F. Bloch, G. Pialoux, et al.
Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirina for severe chronic hepatitis C in HIV-infected patients.
AIDS, 14 (2000), pp. 1656-1658
[74.]
V. Soriano, J. García-Samaniego, R. Rodríguez-Rosado, J. González, J. Pedreira.
Hepatitis C and HIV infection: biological, clinical and therapeutic implications.
J Hepatol, 31 (1999), pp. 119-123
[75.]
A. Haztakis.
HIV and hepatitis.
AIDS, 14 (2000), pp. 5
[76.]
G. Morsica, A. De Bona, C. Uberti, G. Sitia, R. Finazzi, A. Lazzarin.
Ribavirin therapy for chronic hepatitis C does not modifiy HIV viral load in HIV positive patients under HAART.
AIDS, 14 (2000), pp. 1656-1658
[77.]
R. Wasserman, N. Brau, T.I. Hassanein, E. Bini, M. Sulkosky, D. Dieterich.
Once weekly epoetin alpha increases hemoglobin and decreases RBV discontinuation among HCV infected patients who developed anemia on RBV/INF therapy.
Hepatology, 32 (2000), pp. 223A
[78.]
V. Soriano, R. Rodríguez-Rosado, J. García-Samaniego.
Management of chronic hepatitis C in HIV-infected patients.
AIDS, 13 (1999), pp. 539-546
[79.]
M. Den Brinker, F. Wit, P. Werthein-van Dillen, S. Jurriaans, J. Weel, R. van Leeuwen, et al.
Hepatitis B and C virus co-infection and the risk for heptotoxicity of HAART in HIV infection.
AIDS, 14 (2000), pp. 2895-2902
[80.]
M. John, J. Flexman, M. French.
Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with protease inhibitors: an immune restoration disease?.
AIDS, 12 (1998), pp. 2289-2293
[81.]
Dieterich DT. HCV in HIV: challenges and opportunities. Disponible en: http://www.prn.org/_frms/vol6/num1/dieterich_frm.htm. March, 2001.
[82.]
J. Arribas, C. Ibañez, B. Ruiz-Antoran, J. Pena, C. Esteban-Calvo, J. Frias, et al.
Acute hepatitis in HIV-infected patients during ritinavir treatment.
AIDS, 12 (1998), pp. 1722-1724
[83.]
M. Puoti, A. Patroni, L. Pan, L. Tomasoni, B. Zanini, M.G. Antonini, et al.
Hepatotoxicity asociated with Non Nucleoside Reverse Transcriptase Inhibitors (NNTRI) in 427 adults infected with Human Immunodeficiency Virus. 8th European Conference on Clinical Aspects and Tratment of HIV-infection.
Athens 28-31 October, Abstract, (2001), pp. 249
[84.]
F. Torriani, V. Soriano.
Chronic hepatitis C in HIV infected-individuals.
AIDS Reviews, 2 (2000), pp. 168-177
[85.]
N. Yao, T. Hesson, M. Cable, Z. Hong, A.D. Kwong, H.V. Lee, et al.
Structure of hepatitis C virus RNA helicase domain.
Natr Struct Biol, 4 (1997), pp. 463-467
[86.]
R.A. Love, H.E. Parge, J.A. Wickersham, Z. Hostomsky, N. Habuka, E.W. Moomaw, et al.
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsine-like fold and a structural zinc binding site.
Cell, 87 (1996), pp. 331-342
[87.]
H.E. Blum.
Genet therapy for chronic viral hepatitis.
Gastroenterol Clin Biol, 21 (1997), pp. A157
[88.]
F. von Weizsacker, S. Wieland, J. Kock, S. Offensperger, D. Moradpour, H.E. Blum.
Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.
Hepatology, 26 (1997), pp. 251-255
[89.]
P.j. Welch, S. Yei, J.R. Barber.
Ribozyme gene therapy for hepatitis C virus infection.
Clin Diagn Virol, 10 (1998), pp. 163-171
[90.]
O. Nussbaum, E. Ilan, R. Eren, A. Zauberman, Y. Porat, L. Neville, et al.
Evaluation of human monoclonal antibodies to HCV in the HCV-trimera mode: a mouse model for HCV infection.
Programs an abstracts of the 36th Annual Meeting of the European Association for the Study of Liver. Prague April 18-22 GS, (2001), pp. 5-30
[91.]
R. Bruck, O. Genina, H. Aeed, R. Alexiev, A. Nagler, Y. Avni, et al.
Halofunginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Hepatology, 33 (2001), pp. 379-386
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
